John Tagliamonte

WntRx Pharmaceuticals develops non-toxic selective drugs for the treatment of patients with colorectal cancer and critical unmet medical needs. It specializes in the development of oncogenic-specific inhibitors of Wnt signaling, a pathway aberrantly activated in a multitude of cancers. The company was founded in 2013 and is headquartered inBoston, Massachusetts.